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Abstract
Background: Ovarian cancer has the highest mortality rate of all gynecologic malignancy. The receptor tyrosine
kinases (RTKs), including EGFR, ERBB2, PDGFR, VEGFR and MET, are activated in subsets of ovarian cancer,
suggesting that these kinases might represent novel therapeutic targets. However, clinical trials have not or just
partially shown benefit to ovarian cancers treated with EGFR, ERBB2, or PDGFR inhibitors. Despite multiple RTK
activation in ovarian cancer pathogenesis, it is unclear whether transforming activity is dependent on an individual
kinase oncoprotein or the coordinated activity of multiple kinases. We hypothesized that a coordinated network of
multi-RTK activation is important for the tumorigenesis of ovarian cancers.
Results: Herein, we demonstrate co-activation of multiple RTKs (EGFR, ERBB2, ERBB4, MET and/or AXL) in individual
ovarian cancer cell lines and primary tumors. We also show that coordinate inhibition of this multi-kinase signaling
has substantially greater effect on ovarian cancer proliferation and survival, compared to inhibition of individual
activated kinases. The inhibition of this multi-RTK signaling by HSP90 suppression results in profound pro-apoptotic
and anti-proliferative effects, and is associated with the inactivation of RTK downstream PI3-K/AKT/mTOR and RAF/
MAPK signaling.
Conclusion: These studies suggest that anti-multiple RTK strategy could be useful in the treatment of ovarian
cancer.
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Background
Ovarian cancer is a leading cause of cancer death among
women in Western Europe and the United States, which
has the highest mortality rate of all gynecologic malig-
nancy [1,2]. Ovarian cancer histologic subtypes include
epithelioid (serous, endometrioid, mucinous, clear cell
and undifferentiated) and non-epitheliod [3], of which
the epithelioid subtype accounts for 90% of ovarian
malignancies [4]. Although more than 70% patients have
increased 5-year survival rates after surgery followed by
chemotherapy and second-line therapies [5], the low
overall cure rates and the intolerable side effects of sys-
temic chemotherapy asks for the development of novel
and more effective pharmacological interventions.
An improved understanding of ovarian cancer biology -
including crucial growth factor signaling pathways - is
needed for the identification of biologically rational
targets for novel therapies.
The increasing evidences suggest that receptor
tyrosine kinase (RTK) activation participates in the
oncogenic progression from nonneoplastic mesothelial
lining of the ovaries or the fallopian tube epithelium to
epithelial ovarian cancer. Epidermal growth factor recep-
tor (EGFR) is amplified in approximately 4%-22% of
ovarian cancer and activating EGFR mutations is rare
with a frequency of 4% or less [6-8]. EGFR upregulation
is detected in ~60% ovarian cancer and associated with
increased tumor cell proliferation, advanced tumor
grades and poor patient prognosis [6,7]. Furthermore,
the EGFR small molecular inhibitors gefitinib and erloti-
nib inhibited EGFR-mediated AKT and MAPK phos-
phorylation and decreased tumor cell proliferation in
some ovarian cancer cell lines and tumor xenograft
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present in a subset of epithelial ovarian cancer and ser-
ous carcinoma [9,10]. Anti-ERBB2 Trastuzumab and
lapatinib inhibited the proliferation and tumor growth
in ovarian cancers with ERBB2 upregulation [3,9,11].
More recently, an activated ERBB3/NRG1 autocrine
loop has been demonstrated to support tumor cell pro-
liferation in a subset of primary ovarian cancers and
ovarian cancer cell lines [12]. The MET receptor tyro-
sine kinase and its ligand (hepatocyte growth factor,
HGF) are highly expressed in ovarian cancers, and MET
inactivation by small molecular inhibitor and siRNA
reduced tumor burden and metastasis in nude mice
with ovarian cancer [13,14]. EPHA2 is overexpressed in
many types of human cancer but is absent in normal
epithelial tissues [15]. EPHA2 inhibition by dasatinib or
a novel immunoconjugate containing an anti-EPHA2
monoclonal antibody linked to a chemotherapeutic
agent, shows antitumor activity against EPHA2-positive
ovarian cancer cell lines and mouse tumor models
[15,16]. Platelet derived growth factor receptor (PDGFR)
is expressed in 50-80% of ovarian cancers [17]. High
expression of PDGFR has been correlated with aggres-
sive tumor phenotypes including high proliferation
index and advanced histologic grade [18]. PDGFR inacti-
vation by both RNAi and a neutralizing antibody, results
in significant anti-proliferative effects in ovarian cancer
cells [19]. High expression of VEGF (vascular endothe-
lial growth factor) and its receptors (VEGFR-1, -2, and-
3) has been associated with poor prognosis in ovarian
cancer [20,21]. Anti-angiogenic Pazopanib or sunitinib
suppressed tumor growth in preclinical ovarian cancer
models [2]. The AXL receptor tyrosine kinase protein,
and its ligand Gas 6 (growth arrest-specific gene 6) are
expressed significantly higher in ovarian cancers than in
normal ovaries, although its role in the tumorigenesis of
ovarian cancer needs further studies [22].
In addition, numerous evidences have indicated the
association between TP53 mutations in ovarian cancer
and prognosis. Most high-grade serous carcinomas are
characterized by TP53 mutations and lack of mutations
of KRAS, BRAF,o rERBB2 [23]. Mutant p53 is almost
invariably present and plays a crucial role in the mole-
cular pathogenesis of high grade serous carcinoma [24].
In recent years, RTK-targeted cancer therapies - for
example, anti-ERBB2 in breast cancer [25], anti-KIT and
PDGFA in gastrointestinal stromal tumors (GISTs) [26],
anti-BCR-ABL in chronic myelogenous leukemia [27]
and anti-EGFR in non-small-cell lung cancer [28] - have
seen widespread clinical use. However, despite the
abovementioned evidence for tyrosine kinase activation
in ovarian cancer pathogenesis, targeted anti-kinase
therapies just had only minimal or partial clinical
response in patients with ovarian cancer [2,3]. In the
current studies we demonstrate the simultaneous
activation of multiple RTKs - including EGFR, ERBB2,
MET, and/or AXL - in individual ovarian cancer cell
lines and primary tumors. We also showed that HSP90
inhibition is a compelling approach to inactivate multi-
ple RTKs. The inhibition of multiple RTKs had superior
effect in maximizing apoptosis and anti-proliferation
compared to the inactivation o fa n ys i n g l eR T Ki n h i b i -
tion in these models. These studies highlight multiple
RTK inactivation by HSP90 inhibition as a novel
therapeutic strategy in ovarian cancer.
Materials and methods
Antibodies and reagents
Monoclonal antibodies to EGFR (immunoprecipitation),
phosphotyrosine (PY99), p53 and PCNA and polyclonal
antibodies to EGFR, ERBB4, MET and AXL were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Polyclonal antibodies to AKT and cleaved caspase 8 were
from Cell Signaling Technology (Beverly, MA, USA).
Antibodies to ERBB2, MAPK, and PARP were from
Zymed/Invitrogen Laboratories (Invitrogen life Technol-
ogies, Carlsbad, CA, USA). Phospho-specific antibodies
and monoclonal antibody to S6 were from Cell Signaling
Technology. Monoclonal antibody to p27 was from BD
Transduction Laboratories (San Jose, CA). Monoclonal
antibody to b-actin, lentiviral AXL shRNA constructs,
and polybrene were from Sigma-Aldrich (St, Louis,
MO, USA). Targeting AXL sequences: GCTGTGAA-
GACGATGAAGATT (shRNA1); CTTTAGGTTCTTTG
CTGCATT (shRNA2); CGAAAGAAGGAGACCCGT-
TAT (shRNA3). Control scrambled shRNA: AAGUU-
CAG GUCGAUAUGUGCA.
Human Phospho-RTK Array Kit was from R&D Sys-
tems (Minneapolis, MN, USA). 17-allyloamino-17-
demethoxygeldanamycin (17-AAG) and gefitinib were
obtained from LC Laboratories (Woburn, MA, USA)
and PHA-665752 was from Tocris Biosciences (St.
Louis, MO, USA). AUY922 was obtained from Selleck
(Shanghai, China). All inhibitors were reconstituted in
DMSO. Protein A- and Protein G-sepharose beads were
purchased from Zymed Laboratories (Invitrogen Life
Technologies).
Ovarian cancer cell Lines
Ovarian cancer cell lines derived from serous (SKOV3
and OVCA429), and clear cell (ES2) adenocarcinomas
were used in this study. Ovarian cancer cells are kind
gifts from Dr. Ross Berkowitz in the Laboratory of
Gynecologic Oncology at Brigham and Women’s Hospi-
tal and Harvard Medical School. Ovarian cancer cell
lines were maintained in RPMI 1640 with 10% fetal
bovine serum (FBS) containing penicillin/streptomycin
and L-glutamine.
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All frozen tumor specimens (Chinese patients) were
obtained from Shengjing Hospital of China Medical
University. These studies were approved by the China
Medical University Institutional Review Board, under a
discarded tissues protocol. p1, p2, p3, p8, p9, p10, p11,
p12, p13, and p14 were epithelioid type ovarian cancers;
p4, p6, and p15 were non-epithelioid type ovarian can-
cers; and p5 and p7 were borderline mucinous
cystadenomas.
Phospho-RTK array analysis
The Human Phospho-RTK Array Kit was used to deter-
mine the relative levels of tyrosine phosphorylation of
42 distinct RTKs. Phospho-RTK arrays were performed
as product protocol. Briefly, After serum starved for
2 h, SKOV3, OVCA429, and ES2 lysates were prepared
using lysis buffer (1% NP-40, 50 mM Tris-HCl pH 8.0,
100 mM sodium fluoride, 30 mM sodium pyropho-
sphate, 2 mM sodium molybdate, 5 mM EDTA, 2 mM
sodium orthovanadate) containing protease inhibitors
(10 μg/mL aprotinin, 10 μg/mL leupeptin, 1 mM phe-
nylmethylsulfonyl fluoride). The arrays were incubated
with 500 μg of protein lysates overnight at 4°C after
blocking 1 h by using Array Buffer1. The arrays were
washed and incubated with a horseradish peroxidase-
conjugated phospho-tyrosine detection antibody
(1:5000). Detection was by chemiluminescence (Immo-
bilonTM Western, Millipore Corporation, MA), cap-
tured using a FUJI LAS 1000-plus chemiluminescence
imaging system.
Protein lysate preparations and immunoblotting
Phosphorylation of RTK and downstream signaling was
performed by immunoblotting ovarian cancer cell
lysates after treatment with 17-AAG or AUY922 for 4
h in serum free medium. Total RTK expression, prolif-
eration and apoptosis marker immunoblotting studies
were performed using cell lysates after 48 h treatment
in serum containing media. Frozen tumor samples
were diced into small pieces in cold lysis buffer on dry
ice and homogenized using a Tissue Tearor (Biospec
Products, Inc. USA) for three or five seconds, 3-5
times, on ice, and the cell lysate was then rocked for
overnight at 4°C. Lysates were spined down by centri-
fugation at 14,000 rpm for 30 min at 4°C, and lysate
protein concentrations were determined using a Bio-
Rad protein assay (Bio-Rad Laboratories Hercules, CA,
USA). Electrophoresis and immunoblotting were per-
formed as described previously [29], with hybridization
signals detected by chemiluminescence (ImmobilonTM
Western, Millipore Corporation, MA) and captured
using a FUJI LAS1000-plus chemiluminescence ima-
ging system.
Immunoprecipitation
Ovarian cancer cell lysates were prepared after serum
starved for 2 h or treatment with 1 μM 17-AAG in
serum free medium for 6 h. One mg of protein lysate
was precleared for 30 min using 30 μlo fp r o t e i nGo r
protein A beads at 4°C. Two μgo fE G F R ,E R B B 2 ,
ERBB4, MET, or AXL antibody was added to the super-
natants and rocked for 2-4 h at 4°C. Then 25 μLo f
sepharose-protein G or -protein A beads were added
and rocked overnight at 4°C, then centrifuged at 14,000
rpm for 2 min at 4°C, after which the sepharose beads
were washed 3 times with 750 μLo fI Pb u f f e r( 2 5m i n /
each time) and once with 750 μL 10 mM Tris-Cl buffer
(pH7.6). Loading buffer (20 μL) was added to the beads
and boiled for 5 min at 95°C.
Lentivirus preparation
Lentivirus preparations were produced by cotransfecting
empty vector pLKO.1puro with AXL shRNA, and helper
virus packaging plasmids pCMV Δ R8.91 and pMD.G
(at a 10:10:1 ratio) into 293T cells. Transfections were
carried out using lipofectamine and PLUS reagent. Len-
tiviruses were harvested at 24, 36, 48, and 60 h post-
transfection. Virus was frozen at -80°C in appropriately
sized aliquots for infection.
Cell Culture and Virus infection
OVCA429 cells were cultured in RPMI 1640 medium
with 10% fetal bovine serum and seeded in six-well
plates. Lentiviral shRNA infections were carried out in
the presence of 8 μg/mL polybrene. Cells were lysed for
western blot analysis at 72 h post-infection.
Cell proliferation and apoptosis assays
SKOV3, OVCA429, and ES2 cells were plated at 4, 000
cells/well in a 96-well flat-bottomed plate (Falcon, Lin-
coln NJ) and cultured in media for 24 hours before
being infected with lentiviral AXL shRNAs or different
inhibitors, which included gefitinib (1 μM), PHA-665752
(1 μM) alone or combination, 17-AAG (0.1, 0.25, 0.5
and 1 μM), and AUY922 (0.1, 0.25, 0.5 and 1 μM). Cell
viability and apoptosis were determined after treatment
with inhibitors for 24 hours, and 3 and 6 days using
the Caspase-Glo 3/7 assay kit and the CellTiter-Glo
luminescent assay from Promega (Madison, WI), and
measured using a Veritas™ Microplate Luminometer
(Turner Biosystems, Sunnyvale, CA). The data were
normalized to the control group (scrambled shRNA or
DMSO). All experimental points were set up in four
replicate wells and independently performed in
triplicate.
Apoptosis was also evaluated using PE Annexin V
Apoptosis Detection Kit I (BD Pharmingen™,U S A ) .
Briefly, SKOV3, OVCA429, and ES2 cells in 6-well
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48 hours, trypsinized and washed twice with cold Hanks
Balanced Salt Solution and treated with 5 μlo fP E
Annexin V and 5 μl 7-AAD in 1X Binding Buffer for 15
minutes at RT (25°C) in dark. The stained cells were
analyzed in a flow cytometer within 1 hour and ModFit
LT (Machitosh) was used to analyze the data.
Cell cycle analysis
SKOV3, OVCA429, and ES2 cells in 6-well plates were
treated with 17-AAG or AUY922 for 48 hours, then
trypsinized and washed once with Hanks Balanced Salt
Solution. For nuclear staining, cells were fixed by 70%
ethanol for 24 h. A propidium iodide (PI)-containing
solution (Roche) was added to the cells and incubated
for 15 minutes at 37°C. The cell suspension was ana-
lyzed on a flow cytometer within 48 hours and ModFit
LT (Machitosh) was used to fit the data.
Statistical analysis
Student’s t-tests was performed to analyze data from
cells treated with control DMSO or 17-AAG/AUY922,
as well as cells treated with control scrambled shRNA
+DMSO or combination of gefitinib, PHA, and AXL
shRNA1/AXL shRNA2. Statistically significant differ-
ences were defined as P < 0.05 and P < 0.01.
Results
Expression and activation of multiple RTKs in ovarian
cancer cells
By phospho-RTK assays, the expression and activation
of EGFR, ERBB2, ERBB4 and MET were activated in
SKOV3 cells, and EGFR, MET and AXL in OVCA429
cells, and EGFR in ES2 cells under serum starved
medium condition (Figure 1).
Activation and/or expression of multiple RTK EGFR,
ERBB2, ERBB4, MET, and AXL in ovarian cancer cell
lines were further validated by immunoblotting with
phospho-specific antibodies; As shown in Figure 2A,
E G F R ,E R B B 2 ,E R B B 4 ,a n dM E Ti nS K O V 3 ,E G F R ,
MET, and AXL in OVCA429, and EGFR in ES2 were
strongly phosphorylated (Figure 2A). EGFR, MET, and
AXL activation in the ovarian cancer lines was compar-
able to that in MESO924 cells (Figure 2A), which are
known to feature strong activation of these RTK [30].
By contrast, activation of EGFR, ERBB2, MET, and AXL
was weak-to-undetectable in Hela cells. Co-activation
and co-expression of multiple RTKs were further con-
firmed in these cells by immunoprecipitation with RTK-
specific antibodies and immunoblotted with phosphotyr-
osine (PY99) antibody (Figure 2B). Immunoblotting
showed strong and moderate p53 expression in ES2 and
OVCA429, respectively, whereas p53 was undetectable
in SKOV3 (Figure 2A).
We further evaluated the simultaneous expression/
activation of multiple RTKs by immunoblotting and
immunoprecipitation in 15 primary ovarian tumors
including 3 non-epithelial ovarian tumor (p4, p6, and
p15), and 12 epithelial ovarian tumors (p1-p3, and p8-
p14) (Figure 2C and 2D). Receptor EGFR, ERBB2, MET,
and AXL were strongly co-activated in most primary
ovarian tumors (Figure 2C and 2D).
We next compared the inhibitionary effect of tumor
cell proliferation between HSP90 inhibitor 17-AAG and
various individual kinase inhibitors. EGFR, MET, and
AXL signaling pathways in OVCA429 cells were blocked
individually by EGFR inhibitor gefitinib, MET inhibitor
PHA665752, or shRNA specific to AXL; various combi-
nation of kinase inhibitors were also performed, As
shown in Figure 3A, the most striking reduction in cell
viability was seen in cells treated with 17-AAG or com-
bination of all 3 kinase inhibitors with ~75% cell
decrease observed. EGFR and MET inhibitors alone or
together had mild or little effects on cell viability. AXL
inhibition by lentiviral shRNA1 and shRNA2 resulted in
50% and 25% inhibition of cell viability in OVCA429,
respectively, whereas combination of EGFR/MET and
AXL inhibition resulted in 65% reduction in viability
(Figure 3A). The AXL shRNA-mediated knockdown
resulted in ~95% (AXL shRNA1) and 60% (AXL
shRNA2 and shRNA3) decrease of AXL protein expres-
sionin OVCA429 (Figure 3B).
Inactivation of multi-RTKs and downstream
intermediates by HSP90 inhibition
The observation that individual RTK inhibitors have
little effect on cell viability (Figure 3A), suggested that
activation of any one RTK is insufficient to sustain ovar-
ian cancer growth and/or survival. Because the effect of
Figure 1 Coactivation of multiple RTKs in ovarian cancer cell
lines. Total cell lysates (500 μg) from SKOV3, OVCA429, and ES2
cells that were maintained under serum starved medium for 2 h
were subjected to phospho-RTK array. Positive duplicated spots for
individual RTK were numbered and indicated on the right of the
array. Two dots at each corner indicate positive controls and eight
dots at the lower right indicate negative controls.
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greater than combination of EGFR, MET, and AXL sup-
pression (Figure 3A), and multiple RTK EGFR, ERBB2,
MET, and/or AXL were simutaneously activated in indi-
vidual ovarian cancer cells (Figure 1 and 2), we hypothe-
sized that the HSP90 inhibition collectively inactivated
RTK downstream intermediates including PI3-K/AKT/
mTOR and RAF/MAPK signaling. HSP90 has crucial
roles in maintaining the conformation and stability of
many activated RTKs, including EGFR, ERBB2, and
MET [31]. We therefore evaluated whether HSP90 inhi-
bition collectively inactived multiple RTKs and their
downstream signaling pathways, which have been impli-
cated in maintaining proliferation and survival in ovar-
ian cancers [3,13].
In SKOV3 and OVCA429, phosphoRTK evaluations of
ovarian cancer total cell lysates demonstrated co-activa-
tion of multiply RTKs (Figure 1A). EGFR, ERBB2,
ERBB4, and MET immunoprecipitations in SKOV3,
E G F R ,M E T ,a n dA X Li m m u n o p r e c i p i t a t i o n si n
OVCA429, and EGFR immunoprecipitation in ES2,
from DMSO vs. 17-AAG treated ovarian cancer cells
confirmed 17-AAG mediated inhibition of multi-RTK
tyrosine phosphorylation, as demonstrated by phospho-
tyrosine (PY99) immunostaining (Figure 4A). Immuno-
blotting evaluations of ovarian cancer total cell lysates
also demonstrated inactivation of EGFR, ERBB2, and
MET after 17-AAG treatment (Figure 4B). Inhibition of
total EGFR, ERBB2, MET and AXL expression was seen
in all ovarian cancer cell lines after treatment with
Figure 2 Immunoblotting and immunoprecipitation evatulations of multi-RTK coactivation in ovarian cancer cell lines and primay
tumors. A) Imunoblotting evaluations of EGFR, ERBB2, ERBB4, MET, AXL and p53 expression and/or activation in ovarian cancer cell lines (SKOV3,
OVCA429 and ES2), mesothelioma cell line (MESO924, positive control), and Hela cell line (negative control). B) The activation of EGFR, ERBB2,
ERBB4, MET, and AXL was validated by immunoprecipitation followed by phosphotyrosine and EGFR, ERBB2, ERBB4, MET, and AXL
immunoblotting in ovarian cancer cell lines (SKOV3, OVCA429 and ES2). C) Imunoblotting evaluations of EGFR, ERBB2, ERBB4, MET, and AXL
expression and/or activation in ovarian cancer primary frozen tumors (p1-p15). D) The activation of AXL was validated by immunoprecipitation
followed by phosphotyrosine and AXL immunoblotting in ovarian cancer primary frozen tumors.
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(Figure 4C). AKT and S6 were substantially and dose-
dependently inactivated in all three ovarian cancer cell
lines after HSP90 inhibition, whereas MAPK was inacti-
vated in two of the ovarian cancer lines (SKOV3 and
OVCA429) (Figure 4B).
HSP90 regulation of ovarian cancer proliferation
We extended our studies of HSP90 inhibition on
proliferation to several ovarian cancer cell lines. Cell
proliferation, as assessed using an ATP-based cell via-
bility assay (CellTiter-Glo), was strongly inhibited in
all ovarian cancer cell lines after HSP90 inhibition by
17-AAG (Figure 5A). Treatment with 17-AAG showed
more profound anti-proliferative effects at day 6 than
day 3. Cell proliferation IC50s at Day 6 were 350 nM
for SKOV3, and 100 nM for OVCA429, and 750 nM
for ES2, suggesting that 17-AAG anti-proliferative
effects are more pronounced in ovarian cancer cells
with multiply RTK activation (SKOV3 and OVCA429)
than in ovarian cancer with single RTK activation
(ES2). HSP90 inhibition also suppressed the expression
of proliferation cell nuclear antigen (PCNA) prolifera-
tion marker in all three ovarian cancer lines; no
Figure 3 Consequences of single vs. combination tyrosine kinase inhibitor treatments on ovarian cancer viability. A) Cell viability, in
ovarian cancer cell line OVCA429, was evaluated by the CellTiter-Glo luminescence assay after 72 h treatment with EGFR (1 μM gefitinib), MET (1 μM
PHA665752), or AXL (AXL shRNA1 and AXL shRNA2) inhibitor alone and together, and HSP90 inhibitors (1 μM 17-AAG). The data were normalized to
the DMSO control, and represent the mean values (± s.d.) of quadruplicate cultures (*p <0 . 0 5 ,* * P < 0.01, n = 3). B) Imunoblotting evaluations of AXL
expression in OVCA429 cells post-infection AXL shRNA at 72 h.
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these cells (Figure 4C).
The 24 or 48 hour 17-AAG treatments induced apop-
tosis, as evidenced by an increase of caspase3/7 activity
(Figure 5B), the expression of caspase 8, and PARP clea-
vage (Figure 4C). Ovarian cancer lines analyzed at 48 h
post 17-AAG treatment had dramatic increase in apop-
totic cells compared to matched vehicle-treated cells
(Figure 5C and Additional File 1 Table S1). The apopto-
sis was most prominent in SKOV3, the same cell line
showing the highest level of nuclear fragmentation after
17-AAG treatment (Figure 5D).
Cell cycle analyses demonstrated a dose-dependent
G2/G1 block with decreased S-phase population, and
increased apoptotic portion (pre-G1 peak) in cells
treated with HSP90 inhibitior 17-AAG (Figure 5D).
Cell-cycle analysis in SKOV3 and OVCA429 showed
a G2 block after HSP90 inhibition with an increase in
the G2 peak from 12% and 10% in control cells to 24%
and 20% after 17-AAG treatment, respectively (Figure
5D). This was accompanied by a decrease in the S-phase
population from 14% and 13% of control cells to 8% of
17-AAG treated cells, respectively. ES2 cells showed a
mild G1 block after HSP90 inhibition with an increase
in the G1 peak from 74% of control to 78% of 17-AAG-
treated cells (Figure 5D).
HSP90 inhibition by a novel and pharmacologically
favourable agent, AUY922, in ovarian cancer
AUY922 is a novel isoxazole-based HSP90 inhibitor,
causes the degradation of multiple oncogenic cellular
proteins and preclinical data suggest broad antitumor
activity [32]. Because AUY922 has likely clinical advan-
tages compared to 17-AAG, we evaluated AUY922 on
RTK expression, RTK activation cell-cycle checkpoint
protein expression, cell viability and apoptosis.
SKOV3 and OVCA429 were incubated with AUY922
for 48 h and subjected to western blot analyses. The
phosphorylation of EGFR, ERBB2, MET, AXL, AKT,
MAPK and S6 were all inhibited (Figure 6A); the total
E G F R ,E R B B 2 ,M E T ,A X La n dA K Te x p r e s s i o nw e r e
also inhibited (Figure 6B). These alterations were asso-
ciated with upregulation of p27 (Figure 6B), consistent
with cell cycle arrest induced by AUY922. Substantial
reduce in cell viability was detected in both ovarian can-
cer cell lines by AUY922 (Figure 6C), and apoptosis was
evidenced by caspase 8, and PARP cleavage, a significant
increase in caspase 3/7 activity (Figure 6B and 6D), and
ad r a m a t i ci n c r e a s ei na p o p t o t i cc e l l sc o m p a r e dw i t h
matched vehicle-treated cells (Figure 6E and Additional
File 1, Table S1). Cell cycle analyses demonstrated a G2
block in SKOV3 and OVCA429 treated with AUY922
(Figure 6F).
Figure 4 Inactivation of multi-RTKs and downstream intermediates by HSP90 inhibition. A) Inhibition of EGFR, ERBB2, ERBB4, AXL and MET
phosphorylation in cell immunoprecipitates after 4 h 17-AAG (1 μM) treatment in serum-free medium. B) Immunoblotting evaluated effects of
HSP90 inhibitor 17-AAG on RTK EGFR, ERBB2, and MET, and intermediate AKT, S6 and MAPK activation, after 4 h treatment in serum-free
medium. C) Effects of HSP90 inhibitor 17-AAG on EGFR, ERBB2, MET, AXL, PCNA, p53, Caspase 8 and PARP expression in ovarian cancer lines,
after 48 h 17-AAG treatment in serum-containing medium. b-actin stain is a loading control.
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Ovarian cancer has the highest mortality rate of all
gynecologic malignancy. Available therapies, including
surgery, radiation, and chemotherapy, have not substan-
tially improved survival for patients with ovarian cancer.
Thus, there is an urgent need to further characterize
ovarian cancer biologically and validate novel targeted
therapies. Although the increasing evidence indicates
tyrosine kinase activation promotes biological progres-
sion from nonneoplastic mesothelial lining of the ovaries
or the fallopian tube epithelium to epithelial ovarian
cancer, the clinical trials of small molecular tyrosine
kinase inhibitors and monoclonal antibodies to RTK in
patients with ovarian cancer failed to demonstrate clini-
cal benefit [2]. For example, treatment of ovarian
tumors with anti-EGFR or PDGFR agents had little
response [33,34]. The reasons for this lack of efficacy of
anti-RTK agents in ovarian cancer are unknown.
In our initial studies, we have evaluated the phosphor-
ylation and expression of RTKs in individual ovarian
cancer cell lines and primary frozen tumors (Figures 1
and 2). Our results suggested that the simultaneous acti-
vation of multi-RTK (EGFR, ERBB2, ERBB4, MET and/
or AXL) in individual ovarian cancer contribute to the
drug resistance to individual RTK inhibitors in ovarian
cancer. Our results are in line with a recent study show-
ing that cells with coactivation of RTKs were resistant
to chemotherapy [35].
MET is highly expressed at different stages of neoplas-
tic progression and capable of inducing the proliferation
Figure 5 HSP90 regulation of ovarian cancer proliferation and survival. A) Ovarian cancer cell viability was determined by the CellTiter-Glo
assay after 3 and 6 day treatment with HSP90 inhibitor, 17-AAG. The data were normalized to the DMSO control, and represent the mean values
(± s.d.) of quadruplicate cultures (*p < 0.05, **P < 0.01, n = 3). B) Apoptosis was evaluated in ovarian cancer cell lines, at 24 h after treatment
with 17-AAG. Caspase 3/7 activity was measured using a Caspase-Glo luminescence assay. The data were normalized to the DMSO control, and
represent the mean values (± s.d.) from quadruplicate cultures (*p < 0.01, n = 3). C) Apoptosis analyses following 17-AAG (0.5 and 1 μM)
treatment for 48 hours by using PE Annexin V Apoptosis Detection Kit I. D) Cell cycle analyses after 48 hours inhibitor treatment in serum-
containing medium.
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inhibited, after 4 h AUY922 treatment in serum-free medium. b-actin stain is a loading control. B) Inhibition of EGFR, Erbb2, MET, AXL and AKT
expression, with concomitant upregulation of p27, and variable Caspase 8 and PARP cleavage, after 48 h AUY922 treatment in serum-containing
medium. b-actin stain is a loading control. C) Ovarian cancer cell viability was determined by the CellTiter-Glo assay after 72 h treatment with
HSP90 inhibitor, AUY922. The data were normalized to the DMSO control, and represent the mean values (± s.d.) of quadruplicate cultures (*p <
0.05, **P < 0.01, n = 3). D) Apoptosis was evaluated in ovarian cancer cell lines, at 72 h after treatment with AUY922. Caspase 3/7 activity was
measured using a Caspase-Glo luminescence assay. The data were normalized to the DMSO control, and represent the mean values (± s.d.) from
quadruplicate cultures (*p < 0.05, **P < 0.01, n = 3). E) Apoptosis analyses following AUY922 (0.5 and 1 μM) treatment for 48 hours by using PE
Annexin V Apoptosis Detection Kit I. F) Cell cycle analyses after 48 hours inhibitor treatment in serum-containing medium.
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Page 9 of 12of ovarian cancer cells [36]. Several studies confirmed
the important role of HGF/MET signaling in the trans-
formation of surface ovarian epithelial cells and in the
growth and dissemination of ovarian cancer [37,38].
Blocking the MET signaling by the MET inhibitors, PF-
2341066, or by specific MET RNAi had antiproliferative
effects and reduced tumor metastasis in ovarian cancer
cells, possibly by suppressing MET-dependent PI3-K/
AKT and RAF/MAPK signaling pathways [13,14]. In our
present study, PHA-665752, a MET inhibitor, had mild
effect in OVCA429 cell viability (Figure 3A), and PHA-
665752 inhibition of viability did not correlate with
baseline MET tyrosine phosphorylation in ovarian can-
cer (Figure 1 and 2B). Similarly, only a mild effect on
ovarian cancer viability were detected after gefitinib-
mediated EGFR inhibition and the cell death did not
correlate with baseline EGFR tyrosine phosphorylation
(Figure 1 and 2A, 2B and 2C), in spite of strong EGFR
expression in many ovarian cancers (Figure 2A and 2C)
[6,7]. Our findings are in consistent with the lack of effi-
cacy of gefitinib or erlotinib in ovarian cancer clinical
trials [3]. The combination inhibition of EGFR and
MET by gefitinib and PHA665752 (1 μM) had similar
anti-proliferative effects to the inhibition by each of
RTKs (Figure 3A). AXL is another receptor tyrosine
kinase known to be involved in ovarian cancers; AXL
promoted proliferation in glioma cells and breast cancer
cells [39,40], and AXL upregulation and activation was
detected in ovarian cancers over normal ovaries (Figure
1 and 2) [22]. Our studies showed that AXL knockdown
by RNA interference inhibited cell proliferation by 65%
in OVCA429 cells, and the combination inhibition of
EGFR, MET, and AXL inhibition resulted in 75%
decrease in cell viability (Figure 3A).
HSP90 inhibition has shown anti-proliferative effects
against ovarian preclinical models [41-43], however, the
molecular mechanisms are unclear. Our studies show
that multiple receptor tyrosine kinases are co-activated
in individual ovarian cancer cells. The HSP90 inhibition
led to the dephosphorylation and degradation of EGFR,
ERBB2, ERBB4, MET and AXL in various ovarian can-
cer cells. Our studies showed that the phosphorylated
forms of the RTKs were more sensitive to HSP90 inhibi-
tor-mediated degradation (Figure 4A, B and 6A). Many
protein kinases are degraded by a phosphorylation-
dependent ubiquitin-proteasome system (UPS) [44].
CDC37, a co-chaperone of HSP90, stabilizes client pro-
teins following their interaction with HSP90 and regu-
lates protein kinase activity [45]. Treatment with HSP90
inhibitors such as 17-AAG or AUY922 led to UPS-
dependent degradation of activated RTKs and total
RTKs in a time-dependent manner, as those seen in
GISTs and mesothelioma with HSP90 inhibition [46,30].
Moser C, et al. also pointed out the cancer selectivity
and antitumoral effects of HSP90 inhibitors are regu-
lated by affecting multiple targets and pathways, and
identification of biomarkers such as RTK will be crucial
for successful design and monitoring of targeting HSP90
therapies [47]. Furthermore, inhibition of HSP90 affects
the tumor microenvironment by medicating non-malig-
nant cells, such as endothelial cells and pericytes [47].
HSP90 inhibition by 17-AAG or AUY922 induced G1/
G2 arrest and dramatic cell apoptosis (Figure 4C and
5B-D; Figure 6B and 6D-F). While treatment with 17-
AAG induced the most markedly apoptosis in SKOV3
(Figure 5B, Figure 5C and Additional File 1, Table S1),
AUY922 induced dramatic apoptosis in both SKOV3
and OVCA429 cells (Figure 6D, E and Additional File 1
Table S1).
The HSP90 inhibitor had a similar or greater anti-
proliferation effect on various ovarian cancer cells
compared to the combination inhibition of multiple
RTKs (Figure 3A). Our studies also showed that indivi-
dual RTK inhibitors have little or mild effect on ovar-
ian cancer cell viability (Figure 3A). Taking together,
these results suggested that the drugs targeting multi-
ple RTK signaling simultaneously such as HSP90 inhi-
bitors may be more effective in the treatment of
ovarian cancer. So far, thirteen HSP90 inhibitors have
been tested in clinical trial evaluation [48,49].
Although the HSP90-targeted drugs are currently not
approved for clinical use, considerable progress has
b e e nm a d eo nv a r i o u st u m o r st r a i l si n c l u d i n gm e t a -
static melanoma, multiple myeloma, non-small cell
lung cancer, and leukaemia [48]. The HSP90 inhibitor
17-AAG has substantial activity against various human
cancers in pre-clinical models by selectively degrading
HSP90-client oncoproteins [50,51]. 17-AAG is now in
Phase III validation with an improved formulation that
overcomes several toxicities [49]. Several chemically
different HSP90 inhibitors with improved oral biologi-
cal availability have also been testing in clinic trial or
will enter clinical trails [48]. Our current studies pro-
vided a mechanistic basis for the use of HSP90 inhibi-
tors in ovarian cancer therapy.
Common downstream signaling of multiple RTK
activation include the activation of PI3-K, mTOR and
MEK, which play key roles in regulating survival, pro-
tein translation, and proliferation, respectively. In addi-
tion, these key signaling intermediates are also
involved in differentiation, tissue invasion, angiogen-
esis, cell size, and cell responses to nutrients [52-54].
We have studied the activation of PI3-K, mTOR and
MEK signaling in ovarian cancer cells treated with
HSP90 inhibitor. HSP90 inhibition resulted in the inac-
tivation of the AKT, S6, and MAPK (Figure 4B and
6B), which dramatically decreased cell viability by
inducing cell apoptosis and G1/G2 cell cycle arrest
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Page 10 of 12(Figure 5, and 6) in each ovarian cancer cell line.
Although p53 mutation plays the central roles in the
molecular pathogenesis of high grade serous carcinoma
[23], the expression of wild type (OVCA429) and
mutant p53 (clear cell line ES2) was not affected after
HSP90 inhibition by 17-AAG (Figure 4C).
Conclusions
Our studies demonstrated that simultaneous activation
of multi-RTKs including EGFR, ERBB2, MET, and AXL
contributes to ovarian cancer cell proliferation and sur-
vival. HSP90 inhibition led to the inactivation of these
receptor tyrosine kinases and suppress the downstream
survival/proliferation signaling. These studies suggest
that anti-multiple RTK strategy could be useful in the
treatment of ovarian cancer.
Additional material
Additional File 1: Apoptosis analyses (%) after 17-AAG and AUY
treatment in ovarian cancer cell lines (SKOV3, OVCA429, and ES2).
Apoptosis analyses following 17-AAG (0.5 and 1 μM) and AUY922 (0.5
and 1 μM) treatment for 48 hours by using PE Annexin V Apoptosis
Detection Kit I. 17-AAG or AUY922 treatment had dramatic increase in
apoptotic cells compared to matched vehicle-treated cells.
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